HomeAMRN • NASDAQ
Amarin Corporation plc
$0.89
Mar 28, 9:55:03 AM GMT-4 · USD · NASDAQ · Disclaimer
US listed securityIE headquartered
Previous close
$0.89
Day range
$0.88 - $0.90
Year range
$0.65 - $1.56
Market cap
365.37M USD
Avg Volume
1.84M
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
74.71M-17.21%
Operating expense
49.73M-32.22%
Net income
-5.78M-775.35%
Net profit margin
-7.74-914.74%
Earnings per share
0.00-100.00%
EBITDA
-3.87M56.98%
Effective tax rate
-136.06%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
320.66M3.65%
Total assets
831.68M-6.15%
Total liabilities
279.59M-3.87%
Total equity
552.10M
Shares outstanding
410.67M
Price to book
0.66
Return on assets
-1.38%
Return on capital
-2.04%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-5.78M-775.35%
Cash from operations
-645.00K-141.56%
Cash from investing
-71.00M-155.22%
Cash from financing
83.00K118.42%
Net change in cash
-71.56M-172.83%
Free cash flow
-13.91M41.13%
About
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Founded
Mar 1, 1989
Employees
275
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu